LUCD
Lucid Diagnostics Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Lucid Diagnostics has 6 disclosed suppliers and 5 disclosed customers in SEC filings.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
SentenceEsoGuard and EsoCheck are based on patented technology licensed by Lucid from Case Western Reserve University ("CWRU").
LUCD 10-Kaccession 0001437749-26-009805
SentenceEsoCheck is currently manufactured for us by our partners Coastline International ("Coastline"), a high-volume device manufacturer, and Sage Product Development.
LUCD 10-Kaccession 0001437749-26-009805
SentenceDiagnostics Support Services manages warehousing, logistics, fulfillment and customer support of our products.
LUCD 10-Kaccession 0001437749-26-009805
SentenceEsoCheck is currently manufactured for us by our partners Coastline International ("Coastline"), a high-volume device manufacturer, and Sage Product Development.
LUCD 10-Kaccession 0001437749-26-009805
SentenceOther commercial channels include our cash-pay program targeting concierge medicine, arrangements with health systems for comprehensive, integrated esophageal precancer testing programs, and an EsoGuard Telemedicine Program, in partnership with UpScript, LLC, an independent third-party telemedicine provider, that accommodates EsoGuard self-referrals from direct-to-consumer marketing.
LUCD 10-Kaccession 0001437749-26-009805
SentenceOn January 21, 2026, the Company announced that it has been awarded a contract by the U.S. Department of Veterans Affairs for its EsoGuard® Esophageal DNA Test, expanding access to esophageal precancer testing across the nation's largest integrated healthcare system, which serves more than nine million enrolled veterans annually.
LUCD 10-Kaccession 0001437749-26-009805
SentenceOn March 13, 2025, the Company announced that Highmark Blue Cross Blue Shield, an independent licensee of the Blue Cross and Blue Shield Association, has issued a positive coverage policy for non-invasive screening of esophageal precancer and cancer in New York state.
LUCD 10-Kaccession 0001437749-26-009805
SentenceOn June 18, 2025, the Company announced that Hoag, a nationally recognized regional healthcare delivery network, launched a comprehensive, integrated esophageal precancer testing program using the Company's EsoGuard® Esophageal DNA Test.
LUCD 10-Kaccession 0001437749-26-009805
SentenceA substantially identical LCD was published by Noridian Healthcare Solutions, the MAC whose geographic jurisdiction covers our CLIA laboratory in Lake Forest, CA.
LUCD 10-Kaccession 0001437749-26-009805
SentenceThis allowed us to engage directly with Medicare contractor Palmetto GBA and its MolDx Program on CMS payment and coverage.
LUCD 10-Kaccession 0001437749-26-009805
Lucid Diagnostics Inc.
0.41
Linked news
Expected move
No implied move.